Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal irinotecan in Chinese patients with advanced pancreatic cancer
ChiCTR2300078041Phase 4Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Dec 2023
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of nanoliposomal irinotecan in pancreatic cancer (PC) (3 cohorts), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Progression-free survival. Started Dec 2023; status: recruiting.
02
Drugs
nanoliposomal irinotecan
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2300078041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078041.